Last reviewed · How we verify
Nasulin
At a glance
| Generic name | Nasulin |
|---|---|
| Also known as | Intranasal insulin spray 1%, insulin |
| Sponsor | CPEX Pharmaceuticals Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Intranasal Insulin and Its Effect on Postprandial Glucose Metabolism in Comparison to Subcutaneous Insulin (Phase 2)
- Effects of Nasulin v.Placebo on Blood Glucose Control in Patients With Type 2 DM Treated With Basal Insulin & Oral Antidiabetic Meds, Excluding Secretagogues in Phase 2A, Randomized, Parallel, Double- (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nasulin CI brief — competitive landscape report
- Nasulin updates RSS · CI watch RSS
- CPEX Pharmaceuticals Inc. portfolio CI